IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
The Role of HSP72 in Patient with Graves ‘disease and Non-autoimmune Hyperthyroidism in AL-Najaf Province

Author: EMAN NADHAIF, MUHAMED ALI S. AL KABE, ISRAAKETABAL YASIRI, ZAYTOON A. ALKHAFAJI
Abstract: Graves ' disease (GD) is an autoimmune thyroid disease defined by the production of stimulating autoantibodies to the thyroid-stimulating hormone receptor (TSHR) (TSAb) that induce a sustained state of hyperthyroidism in patients. This study aimed to evaluate the role of Heat Shock Protein 72 "HSP72” in patients with Graves' disease in comparison with other non-autoimmune hyperthyroidism in AL-Najaf province. A case control study included patients with early diagnosis of thyrotoxicosis were randomly selected in endocrine center/Al Sadder Medical city. Whole blood samples were collected from 60 patients and sent into thebiochemistry department of internal Laboratory of AL-Sadder Medical City/ Najaf/Iraq, from the period between Sep. 2017 till Apr. 2018. Hyperthyroidism patients were subdivided into two groups: Autoimmune hyperthyroidism "Graves' disease" patients group and Nonautoimmune hyperthyroidism patients group, depending on Anti-TSHR Abs and Anti-TPO Abs. Healthy control group of 40 people who had no history or clinical evidence of hyperthyroidism or any chronic disease. Patients with hyperthyroidism under treatment and pregnant women were excluded from the study. The parameter studied in this work was: Heat Shock Protein 72 "HSP72". Our study showed that significant difference (P=0.05) between Graves’ disease patients, non-autoimmune hyperthyroidism patients and healthy control groups (114.8279, 110.7479 and 67.7500, respectively). In anti-HSP72 antibody that has been detected in sera of Graves' disease patients. levels of antihsp72 antibodies demonstrated in GD patients had higher index than that of control subjects. However, the absence of a correlation with disease severity or activity makes it unlikely that hsp72 antibodies play an important role in the pathogenesis of GD.hsp72 antibody should be investigated thoroughly to correlate it along with the prognosis and severity of GD.
Keyword: hsp72 antibody,autoimmune disease, Grave’s Disease.
DOI: https://doi.org/10.31838/ijpr/2019.11.02.033
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477